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Summary
With increasing number of therapies available for the treatment of multiple
myeloma, it is timely to examine the course of patients’ journeys. We
investigated patient characteristics, treatment durations and outcomes, and
symptom burden across the treatment pathway in Belgium, France, Ger-
many, Italy, Spain, Switzerland and the UK. In total, 435 physicians retro-
spectively reviewed 4997 patient charts. Profiles of patients diagnosed with
multiple myeloma during the last 12 months were similar across countries;
bone pain was the most common presentation. Median duration of first-
line therapy was 6 months, followed by a median treatment-free interval of
10 months; both these decreased with increasing lines of therapy, as did
time to progression. Depth of response, as assessed by the treating physi-
cian, also decreased with each additional line of therapy: 74% of patients
achieved at least a very good partial response at first line, compared with
only 11% at fifth line. Deeper responses were associated with longer time
to progression, although these were physician-judged. Toxicities and co-
morbidities increased with later treatment lines, and were more likely to
have led to discontinuation of treatment. These real-world data provide an
insight into patient outcomes and treatment decisions being made in clini-
cal practice.
Keywords: multiple myeloma, real-world practice, patient chart review,
duration of therapy, depth of response.
Since the start of the 21st century, traditional melphalan-
based regimens for the treatment of multiple myeloma
(MM) have largely been replaced by novel agents (with the
exception of high-dose melphalan). These new agents include
the immunomodulatory drugs thalidomide, lenalidomide and
pomalidomide, and the proteasome inhibitors bortezomib
and carfilzomib (http://www.ema.europa.eu/docs/en_GB/doc-
ument_library/EPAR_-_Product_Information/human/003790/
WC500197692.pdf, Richardson et al, 2015; Torimoto et al,
2015). In the last 12 months, the histone de-acetylase inhibi-
tor, panobinostat, the antibodies, daratumumab and elo-
tuzumab, and the oral proteasome inhibitor, ixazomib, have
all been licensed for the treatment of relapsed MM. New reg-
imens and treatment sequences have ultimately improved
outcomes (Benboubker et al, 2014; San-Miguel et al, 2014;
Stewart et al, 2015). Although such regimens have been
assessed in clinical trials, little is known about the current
management of MM in clinical practice.
An important concern in the management of MM is
whether the cumulative burden of relapsing-remitting disease
limits the use of new therapies. Treatment-emergent neuro-
toxicity, gastro-intestinal side effects, infections, thromboem-
bolic events and cytopenias are associated with poor
performance status and are likely to compromise the timely
delivery of treatment and may thus contribute to early dis-
ease progression. Patient recruitment for clinical trials is
highly selective, often using good performance status as an
eligibility criterion and so the extent to which study popula-
tions represent real-world patients is unclear. Information is
therefore needed on how symptom and toxicity burdens
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affect the use of effective myeloma therapies, particularly in
later lines of treatment.
Patients and treating physicians also lack data describing
the periods on and off treatment in large unselected real-
world MM populations. These intervals influence treatment
outcomes and could guide treatment decisions in everyday
clinical practice.
We have conducted a patient chart review in order to
characterize the management of patients with symptomatic
MM in seven European countries.
Methods
This study aimed to map the course of patients with MM
and to investigate the factors that influence treatment deci-
sions at different stages of the treatment pathway.
Physicians and patients
An observational chart review was performed during 2014, in
Belgium, France, Germany, Italy, Spain, Switzerland and the
UK. Physicians were required to obtain prospective approval
of the study protocol and all relevant study documents from
their local ethics committee, if applicable. Ethics committee
approval was received in Germany and Spain in line with
national regulations in these countries. The remaining coun-
tries did not require ethics committee approval because the
study was completely anonymous, with no identifiable
patient information.
Physicians completed an initial questionnaire to ensure
they met the following eligibility criteria: manage at least 10
patients with MM per month; at least 3 years’ clinical prac-
tice experience; and be personally responsible for initiating
treatment in MM patients. Quotas per region and hospital
type were predefined to ensure a representative sample.
In total, 435 haematologists, onco-haematologists, oncolo-
gists and internists who treat patients with MM were
selected. Overall, in all aspects of the chart review, the aim
was to capture data for approximately 7500 patients.
Materials
The chart review consisted of a cross-sectional and a retro-
spective component (Appendix S1), completed concurrently
by participating physicians. In the cross-sectional component,
physicians completed a census form for each patient they
saw with symptomatic MM during a 2–4-week observation
period, collecting information relating to patient characteris-
tics and treatment. In the retrospective component, physi-
cians completed a focus form for 12 patients (14 patients in
the UK) who had completed specific lines of treatment. The
first patient included by each physician was the most recent
who had completed the relevant line of treatment; patients
were selected in reverse chronological order thereafter. Data
collected included patient and treatment characteristics since
diagnosis, disease response and adverse events at the end of
each line of treatment, reasons for stopping treatment, and
planned future treatment at subsequent relapse. Quotas were
predefined by line of therapy in order to ensure sufficient
sample sizes in later lines where there is greater heterogeneity
in patients and treatments (and less information on real-
world patient management).
To ensure consistency, physicians were provided with
information on staging systems (Durie & Salmon, 1975;
Greipp et al, 2005), European Cooperative Oncology Group
(ECOG) performance status, level of response and definitions
of treatment stages.
Results of the cross-sectional part of the study are
described elsewhere (Raab et al, 2016); data from the retro-
spective study component are reported here.
Weighting
The likelihood of inclusion of some patients in the cross-sec-
tional study varies because some patients are seen more fre-
quently in consultation (e.g. newly diagnosed patients, those
experiencing difficulties with their treatment, etc.) than
others (e.g. those on treatment with fewer complications,
those who are between lines of treatment, etc.). Therefore, a
weighting system was put in place to adjust for the likelihood
of inclusion.
Given that physicians were asked to document each
patient seen in consultation during a pre-defined inclusion
period of 2–4 weeks, the probability of seeing each patient
depended on the frequency of the patient’s consultations: if
this frequency is less than or equal to the inclusion period,
the probability that the patient would be included in the
research is 1. However, if the patient has consultations less
frequently than the observation period (e.g. a patient who
has one consultation per month), the inclusion probability is
adjusted. For example: a physician who used a 2-week obser-
vation period in this study could include a patient who is
normally seen in consultation every 4 weeks. Therefore, the
probability of including this patient in the research is 05.
Patients with more frequent consultations were allocated a
lower coefficient than those who were seen less often.
Data for the retrospective component were weighted
according to the data obtained from the cross-sectional por-
tion using a matching technique (Carpenter & Bithell, 2000;
van der Laan & Dudoit, 2003). This weighting was applied to
reduce individual physician bias, so that the retrospective
data were representative of overall treatment practices in
each country. The final pooled analysis was adjusted for
country contribution size.
Statistical analyses
Quantitative variables were described in terms of mean, med-
ian and standard deviation; qualitative variables were
described as absolute percentage for each modality. Logistic
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regression analysis was used to quantify the effect of variables
(patient and disease characteristics) on a dependent factor
(whether or not further treatment was planned). The output
of the logistic regressions was the odds ratio. Significance
was tested using t-tests for quantitative variables (significance
set at P < 005) and v2 tests for categorical variables, with a
two-tailed probability threshold of 005 considered signifi-
cant. No adjustments were made for multiplicity therefore,
the results of significance testing should be considered
hypothesis generating only.
Results
Patient and disease characteristics
A total of 435 physicians retrospectively reviewed 4997
patient charts. In the 6 months before inclusion in the study,
1802 of the patients had been treated up to the end of first
line, 1380 up to the end of second line and 1815 up to the
end of third line or later.
Physician characteristics have been described previously
(Raab et al, 2015). Characteristics of the patients included in
the retrospective chart review are detailed in Table I. Just
over half (58%) of the patients were male and the majority
of patients (64%) were at least 65 years old; 42% were aged
between 65 and 75 years and 22% were over 75 years old.
These characteristics were consistent across lines of treatment
(data not shown). Overall, the mean time between diagnosis
and the inclusion of patients in the study was 19 months for
patients who had completed first-line treatment, 44 months
for those who had completed second-line treatment and
65 months for those who had completed a third or later line
of treatment. However, this differed between countries: at
second line, mean time since diagnosis ranged from
29 months in Germany to 54 months in Italy, and at third
line it ranged from 49 months in Spain to 77 months in
Italy.
Disease characteristics (Table II) are presented for patients
who were diagnosed with MM in the 12 months before
inclusion in the study (n = 831), to best reflect recent diag-
nostic techniques and clinical practice. The most common
reason for diagnosis was bone pain (61%). Almost half
(48%) of patients had more than one symptom or factor
leading to diagnosis (data not shown).
The majority of patients received bortezomib-containing
regimens as first-line treatment (53%); 22% received thalido-
mide-containing regimens and a further 14% received borte-
zomib with thalidomide (Fig 1A). Lenalidomide was rarely
used in first line (2%) but lenalidomide-containing regimens
were the most commonly used combinations at second line
(46%) (Fig 1B).
Treatment duration and treatment-free interval
The duration of treatment and length of the treatment-free
interval differed according to line of therapy (Fig 2). Fig 2
also shows the proportion of patients reaching each subse-
quent line of therapy (these data are derived partly from the
cross-sectional study). The median duration of first-line
treatment was 6 months (including the 7% of all patients
who received consolidation therapy). This was followed by a
median treatment-free interval of 10 months. The median
treatment-free interval was longer for patients who received
stem cell transplant (SCT) than for those who did not (16
vs. 7 months; P < 0001). In the 12% of patients at first line
who received maintenance treatment (defined as a new treat-
ment prescribed after the regularly scheduled first-line treat-
ment is complete and the patient has achieved their
maximum response), the median maintenance treatment
duration was 6 months.
Table I. Patient characteristics at study inclusion.
All Belgium France Germany Italy Spain Switzerland UK
n = 4997 n = 124 n = 827 n = 1190 n = 1005 n = 1014 n = 84 n = 753
Sex (%)
Male 58 52 60 57 57 62 65 58
Female 42 48 40 43 43 38 35 42
Age (%)
<65 years 36 32 33 35 38 38 31 40
65–75 years 42 37 39 46 41 45 52 42
>75 years 22 31 28 19 21 17 18 18
First-line treatment n = 1802 n = 50 n = 314 n = 411 n = 433 n = 170 n = 43 n = 264
Mean time since diagnosis (months) 19 14 23 13 18 17 20 20
Second-line treatment n = 1380 n = 38 n = 241 n = 353 n = 246 n = 253 n = 16 n = 213
Mean time since diagnosis (months) 44 37 53 29 54 39 39 42
Third-line or later treatment n = 1815 n = 35 n = 271 n = 425 n = 327 n = 591 n = 24 n = 276
Mean time since diagnosis (months) 65 72 74 61 77 49 69 62
Percentages may not total 100% because of rounding. Patient numbers for all countries may differ from the total of the individual countries
because of weighting of the data.
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At second line, the median treatment duration was
7 months, followed by a treatment-free interval of 5 months.
Following later lines of treatment, treatment-free intervals
became progressively shorter, with only a 3-month treat-
ment-free interval after third-line treatment, and a 1-month
treatment-free interval after fourth line. The duration of
treatment was also progressively shorter at fourth and fifth
lines.
Depth of response and time to progression
Physicians evaluated the best response achieved at each line
of treatment (depth of response). Given the observational
(non-interventional) nature of the study, these results should
be interpreted cautiously, as physicians’ assessments were
based on their usual practice and not necessarily on conven-
tionally defined criteria (as is the case in clinical trials).
The proportion of patients achieving what their physician
deemed to be a complete response (CR) decreased from 32%
at first line to 4% at fourth line and 2% at fifth line (Fig S1).
Similarly, 74% of patients achieved at least a very good par-
tial response (VGPR) in the first-line setting, compared with
11% at fifth line or later. Overall response rates [≥ partial
response (PR)] also decreased with treatment lines. Patients
who received SCT were significantly more likely to have a
CR at first line than patients who did not receive SCT (47%
vs. 25% of patients; P < 0001).
The time from the start of a line of treatment to disease
progression (time to progression, TTP) diminished in later
therapy lines (Fig 3A). Median TTP for patients who com-
pleted first-line treatment was 18 months, with 18% of
patients progressing after 36 months or more. At second line,
median TTP was 13 months, with 10% of patients progress-
ing after 36 months or more. Median TTP for patients at
third and fourth line was 7 and 5 months, respectively, with
1–3% of patients progressing after 36 months or more.
TTP was associated with the physician-reported depth of
response (Fig 3B–D). After first line, patients in CR had a
median TTP of 30 months, compared with 21 months for
those in VGPR, and 13 months in those in PR. Patients in
CR after second line had a TTP of 24 months, compared
with 19 and 13 months for those in VGPR and PR, respec-
tively. Too few patients achieved CR at third line to estimate
TTP; however, those in VGPR had a median TTP of
15 months, compared with 9 months for those in PR. In
addition, across lines 1–3, about 30% of all patients with a
physician-reported CR did not have disease progression at
36 months after treatment initiation. This percentage was
lower for those with a VGPR (19% at first line, 14% at sec-
ond line, 9% at third line) and lower still in patients with a
PR (9% at first line, 6% at second line, 1% at third line).
Patients who had a physician-reported VGPR or better at
first line were more likely to achieve a VGPR or better at sec-
ond line (53% vs. 21% of patients if they achieved worse
than a VGPR at first line) (data not shown). A similar pat-
tern was observed in later lines of therapy.
Factors associated with ending of treatment and further
(planned) treatment
For patients who had just finished first-line treatment, rea-
sons for ending that line of treatment included stable disease
or remission (55%; no definition of remission was specified
in the questionnaire), planned end of treatment (38%) or
disease progression (10%) (Fig 4).
The proportions of patients ending treatment because of
stable disease or remission decreased with each line, to 13%
of patients at fifth line or later. Patients at first line were
Table II. Disease characteristics at diagnosis.
Disease characteristic Patients, %
Total previous symptomatic multiple
myeloma diagnoses
16
Previous known diagnosis of MGUS 9
Previously diagnosed with smouldering
multiple myeloma
7
Circumstance of diagnosis
Bone pain 61
Anaemia 39
Vertebral fracture 21
Renal dysfunction 20
Hypercalcaemia 19
Other fracture 9
Abnormal sedimentation 7
Incidental diagnosis 7
Infections 3
Spinal cord compression 1
Other 3
Clinical characteristics at diagnosis
≥2 bone lesions 59
Serum beta-2 microglobulin ≥55 mg/l 38
Haemoglobin <85 g/l 36
Serum albumin <35 g/l 25
Calcaemia >3 mmol/l 23
Lactate dehydrogenase >300 u/l 22
Receiving dialysis 2
None of these 7
ECOG performance status at diagnosis
0 18
1 52
2 26
3–4 4
ISS score at diagnosis (among those with known status, n = 815)
I 16
II 35
III 49
ECOG, Eastern Cooperative Oncology Group; ISS, International
Staging System; MGUS, monoclonal gammopathy of unknown sig-
nificance; U, unit.
Disease characteristics are described only for patients diagnosed with
multiple myeloma in the 12 months before inclusion in the study
(n = 831; median age 69 years).
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more likely to have ended that line of treatment as planned
than those at fifth line or later (38% vs. 7%). Only 10% of
patients ended their first line of treatment because of disease
progression but this proportion increased with each line,
reaching 51% at fifth line or later. The proportion of patients
ending treatment because of toxicity or poor performance
status also increased with later lines of therapy (2% in
patients at first line, compared with 20% for those at fifth or
later lines).
Notably, in the subset of patients receiving lenalidomide
at second line (n = 669), only 22% of patients were treated
until progression (data not shown). In 58% of patients
receiving lenalidomide whose treatment was discontinued
before progression the reason cited was stable disease or
remission, and 22% discontinued after reaching a planned
end of treatment. Similar data were seen for patients treated
with lenalidomide at third line (Fig 5).
Physicians were also asked about the next treatment line.
Logistic regression analysis showed that several factors were
significantly associated with the decision to continue to a
further treatment line. Adverse events, comorbidities and old
age were negatively associated with continuation, whereas
good responses to the previous line of treatment, good
performance status, good renal function, young age and pre-
vious SCT were positively associated with planned or
expected progression to a subsequent line of therapy (Fig 6).
Comorbidities and treatment-related toxicity
The most common comorbidities and toxicities at first line
were peripheral neuropathy (all grades, 45% of patients),
anaemia (23%), neutropenia (22%) and thrombocytopenia
(15%). The proportion of patients with one or more toxicity
or comorbidity at the end of treatment increased with lines
of treatment (Fig 7); 60% of patients had at least one toxicity
or comorbidity at the end of the first line, compared with
77% at the end of the fifth line or later. Similarly, the pro-
portion of patients with normal renal function decreased in
later lines of treatment (70% at first line versus 45% at fifth
line or later; data not shown). An exception was peripheral
neuropathy, which did not appreciably increase further until
fifth line, with a notably low level of grade 3 or 4 events.
Toxicities and comorbidities were more likely to negatively
affect planned treatment in later lines than in earlier lines
(Fig S2). After first line, toxicities and comorbidities affected
planned treatment in 23% of patients, compared with 40%
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Fig 1. Treatment distribution: (A) first line
(n = 1802); (B) second line (n = 1380). CDT,
cyclophosphamide + dexamethasone + thalido-
mide; CVD, bortezomib (Velcade) + cy-
clophosphamide + dexamethasone; MPT,
melphalan + prednisolone + thalidomide;
RVD, lenalidomide + bortezomib + dexam-
ethasone; PAD, bortezomib + doxorubicin
(Adriamycin) + dexamethasone; VM, borte-
zomib (Velcade) + melphalan; VMP, borte-
zomib (Velcade) + melphalan + prednisone;
VTD, bortezomib + thalidomide + dexametha-
sone.
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at completion of third-line treatment. Requirement for sup-
portive treatment, need for hospitalization and need for a
treatment holiday all increased in later lines of therapy. More
than half of the patients who required hospitalization
because of a toxicity or comorbidity (5–8% of all patients
who experienced a toxicity or comorbidity) were hospitalized
more than once.
Concomitant medications
Bisphosphonates were the most commonly used concomitant
medication, taken by 55% of patients across all lines. The
proportion of patients treated with analgesics during treat-
ment increased slightly with later lines, particularly the use of
step 3 analgesics [i.e. step 1 (non-steroidal anti-inflammatory
drugs +/ local anaesthetics) plus step 2 (step 1 plus opioid
analgesics when required) plus local anaesthetic neural block-
ade with or without catheter plus sustained-release opioid
analgesic], from 13% at first line to 25% at fifth line and
beyond; P < 0001). Use of granulocyte-colony stimulating
factor also increased in later lines of treatment, as did use of
antivirals and antibiotics. Use of antithrombotic treatments
and aspirin was consistent across lines of treatment (27%
and 23%, respectively) (Fig 8).
1 m 6 m
Diagnosis 
10 m 7 m
3 m 5 m
Start
1L 
Start
2L 
End
2L 
Start
3L 
End
3L 
Start
4L 
End
4L 
Start
5L 
End
5L 
End 1L
induction 
End 1L
maintenance 
4 m1 m 
5 m 6 m 
6 m
Proportion of patients reaching 
this line of therapy (%)   
100%
61%
95%
38%
15%
1%
1L
2L
3L
4L
5L
Treatment-free interval 
Active treatment 
Maintenance treatment 
Median durations in months shown
Mean (95% CI): diagnosis, 2 m (1·60, 2·40); 1L, 8 m (7·74, 8·26); 1L maintenance, 9 m (7·78, 10·22)
Mean (95% CI): interval 1L–2L, 16 m (15·0, 17·0); 2L, 9 m (8·64, 9·36)
Mean (95% CI): interval 2L–3L, 11 m (10·22, 11·78); 3L, 8 m (7·63, 8·37)
Mean (95% CI): interval 3L–4L, 7 m (5·9, 8·1); 4L, 6 m (5·5, 6·5)
Mean (95% CI): interval 4L–5L, 3 m (1·8, 4·2); 5L, 4 m (3·15, 4·85)
Fig 2. Treatment duration and treatment-free intervals. Data on the proportion of patients who had received each line are from the cross-sec-
tional review; data on durations of treatment and treatment-free intervals are from the retrospective review. 1L–5L, first line–fifth line; CI, confi-
dence interval; m, month.
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Discussion
These retrospective data provide valuable information on the
circumstances of diagnosis of MM and real-world outcomes
following treatment, and the factors that influence treatment
decisions across multiple lines of therapy.
In common with other reports (Kyle et al, 2003; Durie,
2011), the majority of patients (61%) in our study had bone
pain at diagnosis. The prevalence of renal dysfunction (20%)
was also in line with other studies (Kyle et al, 2003; Rifkin
et al, 2015). In general, the prevalence of anaemia at diagno-
sis is reported to be about 70% (Kyle et al, 2003; Birgegard
et al, 2006) whereas this was much lower in our study (39%)
and closer to the prevalence (45%) reported in a recent reg-
istry study in the USA (Rifkin et al, 2015). In contrast, the
rate of hypercalcaemia was slightly higher than reported in
other papers (19% vs. 10–15%) (Kyle et al, 2003; Durie,
2011) and 30% of patients in our study presented with a
fracture, indicating advanced disease (Eslick & Talaulikar,
2013). Furthermore, almost half of patients had more than
one sign or symptom of disease at diagnosis, and most
(84%) had an International Staging System (ISS) score of II
or III at diagnosis. These data suggest that patients in Europe
have considerable MM-related organ damage at diagnosis, so
initiatives facilitating earlier diagnosis are warranted.
It is generally accepted that depth of response correlates
with improved outcomes (Lonial & Anderson, 2014); how-
ever, much of the supporting data are from prospective stud-
ies in clinical trial cohorts. Although real-world methods for
measuring high-quality response are likely to be less rigorous
than those used in clinical trials, we found that physician-
evaluated TTP correlated with depth of response. Further-
more, in accordance with published reports (van Rhee et al,
2014), patients who had undergone SCT were more likely to
achieve CR than those who had not. Moreover, efficacy out-
comes were broadly similar to those seen in clinical trials
(Singhal et al, 1999; Richardson et al, 2005; Dimopoulos
et al, 2007; Weber et al, 2007; San Miguel et al, 2013).
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Fig 3. Time to progression (A) by line of treatment, and by depth of response to (B) first-line treatment, (C) second-line treatment, and (D)
third-line treatment. Only patients who had progressed at the time of inclusion in the study were included in this analysis. aThe number of
patients with a CR at third line was too small to make an accurate estimate. 1L–5L, first line–fifth line; CR, complete response; PR, partial
response; VGPR, very good partial response.
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Achievement of CR or VGPR was also associated with a
greater likelihood of receiving a further line of treatment.
These observations suggest that, in a real-world setting,
physicians are making a distinction between CR, VGPR and
lower levels of response that is valid and clinically relevant.
Evidence has shown that, in addition to treatment efficacy,
patients value the potential for treatment-free intervals
(Muhlbacher et al, 2008; Muhlbacher & Nubling, 2011). Data
on treatment duration and treatment-free intervals will help
physicians to provide realistic estimates of how long a patient
is likely to remain on treatment and how long intervals
between treatments can be expected to last, which may prove
useful when discussing treatment options. Not surprisingly,
from the second line onwards, treatment duration and treat-
ment-free interval decreased with each line of treatment.
Similar results have been reported in a study by Kumar et al
(2004) although the duration of each treatment line was
longer in our study, probably reflecting the recent introduc-
tion of more effective treatments, as well as the move
towards extended therapy (e.g. with pomalidomide).
The cross-sectional component of the current research
showed that almost all patients diagnosed with symptomatic
MM who were treated by haematologists received at least
one line of active treatment (95%) whereas only 15%
received a fourth or further line (Raab et al, 2016). Given
the availability of agents that are effective in relapsed and
refractory MM (Singhal et al, 1999; Richardson et al, 2005;
Dimopoulos et al, 2007; Weber et al, 2007; Offidani et al,
2013; San Miguel et al, 2013; San-Miguel et al, 2014; Stewart
et al, 2015), it is perhaps surprising that relatively few
patients receive multiple lines of therapy. About a quarter of
patients completed fourth-line treatment as planned, and
Stable disease/
remission  
As planned  
Progression  
Poor performance
status  
Reason
for ending
treatment 
Toxicity 
Patient refusal 
Death 
End of 2L
(n = 1380)
48% 
26% 
16% 
6% 
4% 
5% 
3% 
End of 3L
(n = 1329)
41% 
20% 
24% 
8% 
2% 
9% 
3% 
End of 4L
(n = 354)
38% 
25% 
27% 
3% 
2% 
11% 
3% 
End of 1L
(n = 1802)
55% 
38% 
10% 
4% 
1% 
Neurological 1%
Infection <1%
Cutaneous <1%
Poor tolerance <1%
Haematological 2%
Neurological 2%
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Infection <1%
Thrombocytopenia <1%
Cutaneous <1%
Respiratory issues <1%
Neurological 2%
Haematological 1%
Thrombocytopenia <1%
Asthenia <1%
Radiotherapy 
    toxicides <1%
Haematological 3%
Anaemia 1%
Myocardial
    infarction 1%
Infection <1%
Neurological 5%
Cutaneous 3%
Digestive issues 1%
Delerious state 1%
Cytopenia 1%
Thrombocytopenia 1%
1% 
0% 
End of 5L+
(n = 132)
13% 
7% 
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3% 
8% 
12% 
4% 
Fig 4. Reasons for ending treatment. Physicians could select more than one reason. 1L–5L, first line–fifth line.
0
10
20
30
40
50
60
P
ro
po
rti
on
 o
f p
at
ie
nt
s 
(%
)
Second line (n = 669)
Third line (n = 497)
Re
mi
ss
ion
As
 pl
an
ne
d
Pr
og
res
sio
n
Po
or 
co
nd
itio
n
Pa
tie
nt 
ref
us
al
To
xic
ity
De
ath Ot
he
r
55
58
31
22
8
5 75
1
10
76
2
5
1
7
Fig 5. Reasons for ending lenalidomide treat-
ment before progression.
Multiple Myeloma: Patient Outcomes in Real-World Practice
ª 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 259
British Journal of Haematology, 2016, 175, 252–264
38% of patients ended fourth-line treatment in remission,
suggesting that patients do benefit from receiving treatment
at this later stage; however, very few reach fifth-line treat-
ment (1%). A better understanding of the reasons for the
increasingly small proportion of patients reaching later lines
of treatment is needed, given the numerous new agents
recently approved for the treatment of MM. One contribut-
ing factor may be the old age of many of these patients, who
will accumulate comorbidities unrelated to MM. Thus,
patients who are younger at diagnosis (i.e. those who were
eligible for SCT) may be more likely to reach later lines and
thus derive the greatest benefit from increasing treatment
options at repeated relapses. This is borne out by the fact
that, despite a longer time since diagnosis, the age distribu-
tion of patients at third-line therapy was similar to that at
first-line treatment. It should also be noted that over half of
patients treated at third line had been diagnosed with MM
more than 5 years ago and may thus have received less than
optimal regimens and supportive care than patients who are
diagnosed with MM today.
A high proportion of patients in early lines ‘ended treat-
ment as planned’, indicating that the physician did not
intend to treat the patient until progression. The association
between longer treatment-free intervals and better quality
of life (Acaster et al, 2013) could explain why physicians
end treatment before progression. Alternatively, treatment
discontinuation could be due to the use of bortezomib- or
thalidomide-containing regimens, for which the prescribing
instructions recommend a fixed number of cycles (http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000823/WC500037050.pdf,
http://www.ema.europa.eu/docs/en_GB/document_library/
EPAR_-_Product_Information/human/000539/WC500048471.
pdf). Surprisingly, patients receiving lenalidomide frequently
discontinued before progression, illustrating how real-world
practice can deviate from the summary of product charac-
teristics http://www.ema.europa.eu/docs/en_GB/document_li-
brary/EPAR_-_Product_Information/human/000717/WC5000
56018.pdf). As patients progressed to later lines, they were
more likely to discontinue as a result of disease progression,
poor physical condition or toxicity. As expected, patients
experiencing toxicity or comorbidities were significantly less
likely to continue to the next line of treatment than
those who did not experience adverse effects. Anaemia was
particularly strongly associated with discontinuation. How-
ever, this a treatable condition so there is an opportunity
Remission/patient stabilised
CR or VGPR
Normal renal status at end of line
No AEs at end of line
SCT
ECOG PS 0–1 at diagnosis
No negative clinical factors at end of line
<65 years old
Neuropathy
≥2 bone lesions
Experienced an SRE
>75
Thrombocytopenia
Upper respiratory infection
Neutropenia
Serum beta-2 microglobulin ≥55 mg/l
History of cardiovascular disease
Serum albumin <35 g/l
AE negatively impacted planned treatement
Anaemia
2·27 (1·98, 2·59)
1·95 (1·71, 2·22)
1·81 (1·59, 2·06)
1·64 (1·43, 1·88)
1·47 (1·28, 1·69)
1·38 (1·20, 1·59)
1·34 (1·16, 1·54)
1·22 (1·06, 1·39)
0·94 (0·83, 1·07)
0·93 (0·82, 1·06)
0·83 (0·73, 0·95)
0·66 (0·57, 0·76)
0·64 (0·56, 0·74)
0·62 (0·52, 0·75)
0·62 (0·54, 0·71)
0·60 (0·50, 0·73)
0·59 (0·49, 0·71)
0·53 (0·45, 0·63)
0·52 (0·45, 0·60)
0·51 (0·45, 0·58)
0
p value
<0·0001
<0·0001
0·0003
0·0021
0·0062
0·0102
0·0384
0·3389
0·2849
0·0432
0·0016
0·0008
0·0030
0·0004
0·0025
0·0018
0·0002
<0·0001
<0·0001
1
Relative probability of receiving a further line of treatment
32
Odds ratio
95% CI
Positive impact on receiving
next line of treatment
No impact on receiving
next line of treatment
Negative impact on receiving
next line of treatment
Fig 6. Association of patient characteristics with the probability of receiving a further line of treatment. Associations between the probability of
receiving a further line of treatment and patient and disease characteristics were calculated using logistics regression analyses. A P value of <005
was considered statistically significant. AE, adverse event; CI, confidence interval; CR, complete response; ECOG PS, European Cooperative
Oncology Group performance status; SCT, stem cell transplant; SRE, skeletal-related event; VGPR, very good partial response.
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to reduce discontinuation rates through better management
of anaemia.
Despite the increasing symptom burden with disease pro-
gression and more advanced lines of therapy, the percentage
of patients who discontinued treatment as a result of toxicity
remained relatively low as treatment lines increased, even at
fourth and fifth line. This could be because patients who are
able to tolerate therapy and who have fewer comorbidities
are more likely to continue to later lines than patients who
experience treatment-related adverse effects. Disease biology
may also play a role, as patients with responsive disease are
likely to have a lower symptom burden and are therefore
66
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13
Biphosphonates
Antiviral treatment
Antithrombotic treatment
Step 1 analgesic
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Antibiotic
Aspirin
G-CSF
Step 2 analgesic
Step 3 analgesic
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(n = 132)
Fig 8. Concomitant medications. 1L–5L, first line–fifth line; ESA, erythropoiesis-stimulating agent; G-CSF, granulocyte-colony stimulating factor;
Step 1 analgesic, mild – requiring non-steroidal anti-inflammatory drugs and, if the pain is postoperative in nature, infiltration with local anaes-
thetics; Step 2 analgesic, moderate – Step 1 plus opioid analgesics when required; Step 3 analgesic: severe – Step 1 and Step 2 plus local anaes-
thetic neural blockade with or without catheter plus sustained-release opioid analgesic. Some patients received more than one level of analgesic in
each line.
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more able to tolerate further treatment. Other factors may be
the availability of agents with better tolerability profiles and
proactive management of toxicities and comorbidities by
physicians.
In contrast to toxicity, poor performance status, which can
be related as much to disease as to adverse effects of therapy,
was an important factor in treatment discontinuation at later
lines. Toxicities and poor performance status may also com-
promise treatment outcomes indirectly by causing treatment
delays and interruptions, resulting in early relapse.
The study had some limitations. Patients who are not
receiving active MM treatment could be managed by differ-
ent physicians and so may be under-represented. Because the
proportion of patients reaching each line of therapy decreases
as therapy lines advance, the records included fewer patients
receiving advanced lines (third line and beyond). The weight-
ing of the cross-sectional component of the research was
based on the date of the next consultation. This method was
selected after testing multiple ways of correcting for the dif-
ference in likelihood of inclusion of different patient types
related to their consultation frequency. However, this
method is based on the assumption that, for any patient who
was seen infrequently and who was documented in the study,
there exist one or more similar patients that are seen infre-
quently and therefore did not have a consultation during the
inclusion period. It is also possible that there remains some
bias towards patients who have more frequent appointments.
For example, patients receiving agents given for short, fixed
durations, such as bortezomib, may be under-represented
compared with those receiving therapy over longer periods,
such as lenalidomide. As this was a retrospective study based
on current patient attendances, there are no survival data. It
should also be noted that only patients who completed a line
of treatment were included, which may mean that the
responses and treatment-free intervals reported are skewed,
as patients who died during a line of treatment will have had
worse responses and may have had shorter treatment-free
intervals. A prospective study is required to address these
issues.
Conclusions
The chart review provides a detailed insight into patient out-
comes at each line of MM treatment in 2014 in Europe.
While the methods used to evaluate outcomes in real-world
clinical practice may not be as rigorous as those used in a
clinical trial setting, the data show the value of physician-
assessed level of response and the information that physicians
are using to make day-to-day decisions about patient man-
agement. Although symptom burden and comorbidities
increase with subsequent lines of therapy, and depth of
response and duration of treatment-free interval decrease, it
is encouraging to note that patients nevertheless benefit from
effective therapies even at advanced lines of therapy. Despite
this, however, only a third of patients received more than
two lines of therapy, and only a minority received more than
three lines. Toxicities play a role in decisions regarding the
next line of treatment, and an unmet need remains for treat-
ments that are better tolerated, along with efficacy in later
treatment lines and improved quality of response. Finally,
improved patient and physician education about the risk–
benefit profile of new regimens may improve the outcomes
of treatment at all stages by minimizing symptom burden
and treatment delays, thereby increasing the number of
patients who can benefit from multiple treatment lines.
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